149 Prevalence of Vitamin D Deficiency Among Hemodialysis Patients and Response to Cholecalciferol

Abstract

Listen

Translate article

PREVALENCE OF VITAMIN D DEFICIENCY AMONG HEMODIALYSIS PATIENTS AND RESPONSE TO CHOLECALCIFEROL Maria Krassilnikova, Anita Mehrotra, Peter Heeger. Mount Sinai School of Medicine, New York, NY, USA The purpose of this study was to determine the prevalence of 25OH Vitamin D deficiency in hemodialysis patients, identify associated factors, and assess response to repletion with cholecalciferol (D3). We consented 52 outpatients at the Mount Sinai Dialysis unit between August and November 2010 for Vitamin D testing. Those patients found to have 25OH Vit D levels < 25 ng/mL were eligible for randomization to treatment with D3 (50,000 IU weekly) or control (standard of care). 25OH Vitamin D levels were measured in a subset of patients (n = 14) after six weeks of follow-up. The prevalence of Vit D deficiency was 94.2%, as defined by a 25OH Vit D level < 30ng/mL, and 26.9% of patients had Vit D levels < 10ng/mL. Mean and median Vit D levels were 16.1 and 14.1 ng/mL, respectively. Selected clinical characteristics of the patient cohort are given in the table below. There was no association between Vit D level and age, gender, race, or dialysis vintage, but Vit D levels negatively correlated with BMI (Spearman’s ρ = -0.355, p = 0.011). After six weeks of D3 repletion (n = 9), 25OH Vit D increased from a mean of 13.7 ng/mL to 36.6 ng/mL (p = 0.001), with no change in serum Ca or 1,25OH Vit D requirements. No change was noted in the Vit D level of control patients (13.3 ng/mL to 13.1 ng/mL, p = 0.943, n = 5). We demonstrate a higher prevalence of Vit D deficiency among hemodialysis patients than previously reported, and an ability to correct this deficiency with oral D3. A study of the effects of D3 repletion on the immune system in these patients is ongoing. Age, years (mean +/SD) 57 +/12 Gender: Male (%) 28 (53.8%) Race: Black (%) 29 (55.8%)